Precigen announces dosing of first patients with ultracar-t® cells manufactured using proprietary ultraporator™ system in ongoing prgn-3005 and prgn-3006 phase 1 clinical trials

Germantown, md., nov. 16, 2020 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical implementation of its ultraporator™ system, a device...
PGEN Ratings Summary
PGEN Quant Ranking